(S (NP (NP (JJ Recent) (NNS advances)) (PP (IN in) (NP (JJ medical) (NN imaging) (NNS techniques)))) (VP (VBP have) (VP (VBN led) (PP (TO to) (NP (NP (JJ significant) (NNS improvements)) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NP (NN prostate) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NNP PCa)) (-RRB- -RRB-)))))))))) (. .))
(S (PP (IN In) (NP (JJ particular))) (, ,) (NP (NP (JJ multi-parametric) (NNP MRI)) (PRN (-LRB- -LRB-) (NP (NN mp-MRI)) (-RRB- -RRB-))) (VP (VBZ continues) (S (VP (TO to) (VP (VB gain) (NP (NP (JJ clinical) (NN acceptance)) (PP (IN as) (NP (NP (DT the) (JJ preferred) (NN imaging) (NN technique)) (PP (IN for) (NP (NP (JJ non-invasive) (NN detection) (CC and) (NN grading)) (PP (IN of) (NP (NNP PCa)))))))))))) (. .))
(S (ADVP (RB However)) (, ,) (NP (NP (DT the) (ADJP (NN machine) (JJ learning-based)) (NN diagnosis) (NNS systems)) (PP (IN for) (NP (NNP PCa)))) (VP (VBP are) (ADVP (RB often)) (VP (VBN constrained) (PP (IN by) (NP (NP (DT the) (JJ limited) (NN access)) (PP (TO to) (NP (NP (VB accurate) (NN lesion) (NN ground) (NN truth) (NNS annotations)) (PP (IN for) (NP (NN training))))))))) (. .))
(S (NP (NP (DT The) (NN performance)) (PP (IN of) (NP (DT the) (NN machine) (NN learning) (NN system)))) (VP (VBZ is) (ADJP (RB highly) (JJ dependable) (PP (IN on) (NP (NP (DT both) (NN quality) (CC and) (NN quantity)) (PP (IN of) (NP (NP (NN lesion) (NNS annotations)) (VP (VBN associated) (PP (IN with) (NP (JJ histopathologic) (NNS findings))))))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (JJ limited) (NN scalability)) (CC and) (NP (JJ clinical) (NN validation))))))) (. .))
(S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP propose) (NP (DT the) (NN baseline) (NNP MRI) (NN model)) (S (VP (TO to) (VP (ADVP (RB alternatively)) (VB learn) (NP (NP (DT the) (NN appearance)) (PP (IN of) (NP (JJ mp-MRI)))) (S (VP (VBG using) (NP (JJ radiology-confirmed) (JJ negative) (NNP MRI) (NNS cases)))) (PP (IN via) (NP (ADJP (NN weakly) (VBD supervised)) (NN learning))))))) (. .))
(S (SBAR (IN Since) (S (NP (NNP PCa) (NNS lesions)) (VP (VBP are) (ADJP (ADJP (JJ case-specific)) (CC and) (ADJP (RB highly) (JJ heterogeneous)))))) (, ,) (NP (NP (PRP it))) (VP (VBZ is) (VP (VBN assumed) (S (VP (TO to) (VP (VB be) (ADJP (VBG challenging)) (S (VP (TO to) (VP (VB synthesize) (NP (NNP PCa) (NNS lesions)) (S (VP (VBG using) (NP (DT the) (NN baseline) (NNP MRI) (NN model)))))))))) (, ,) (SBAR (IN while) (S (NP (NP (PRP it))) (VP (MD would) (VP (VB be) (ADJP (RB relatively) (JJR easier)) (S (VP (TO to) (VP (VB synthesize) (NP (DT the) (JJ normal) (NN appearance)) (PP (IN in) (NP (NN mp-MRI)))))))))))) (. .))
(S (NP (PRP We)) (ADVP (RB then)) (VP (VB utilize) (NP (DT the) (NN baseline) (NNP MRI) (NN model)) (S (VP (TO to) (VP (VB infer) (NP (NP (DT the) (JJ pixel-wise) (NN suspiciousness)) (PP (IN of) (NP (NNP PCa)))) (PP (IN by) (S (VP (VBG comparing) (NP (DT the) (ADJP (JJ original) (CC and) (JJ synthesized)) (NNP MRI)) (PP (IN with) (NP (CD two) (NN distance) (NNS functions)))))))))) (. .))
(S (NP (PRP We)) (VP (VBD trained) (CC and) (VBD validated) (NP (DT the) (NN baseline) (NNP MRI) (NN model)) (S (VP (VBG using) (NP (CD 1,145) (JJ negative) (NN prostate) (JJ mp-MRI) (NNS scans))))) (. .))
(S (PP (IN For) (NP (NN evaluation))) (, ,) (NP (PRP we)) (VP (VBD used) (NP (NP (VBD separated) (CD 232) (JJ mp-MRI) (NNS scans)) (, ,) (VP (VBG consisting) (PP (IN of) (NP (DT both) (JJ positive) (CC and) (JJ negative) (NNP MRI) (NNS cases)))))) (. .))
(S (NP (DT The) (CD 116) (JJ positive) (NNP MRI) (NNS scans)) (VP (VBD were) (VP (VP (VBN annotated) (PP (IN by) (NP (NNS radiologists)))) (, ,) (VP (VBN confirmed) (PP (IN with) (NP (JJ post-surgical) (NN whole-gland) (NNS specimens)))))) (. .))
(S (NP (DT The) (NN suspiciousness) (NN map)) (VP (VBD was) (VP (VBN evaluated) (PP (IN by) (NP (NP (NP (NN receiver) (NN operating) (NN characteristic) (PRN (-LRB- -LRB-) (NNP ROC) (-RRB- -RRB-)) (NN analysis)) (PP (IN for) (NP (NP (NNP PCa) (NNS lesions)) (PP (VBP versus) (NP (JJ non-PCa) (NNS regions) (NN classification)))))) (CC and) (NP (NP (JJ free-response) (NN receiver) (VBG operating) (JJ characteristic) (PRN (-LRB- -LRB-) (NNP FROC) (-RRB- -RRB-)) (NN analysis)) (PP (IN for) (NP (NNP PCa) (NN localization)))))))) (. .))
(S (NP (PRP$ Our) (VBN proposed) (NN method)) (VP (VBD achieved) (NP (NP (NP (CD 0.84) (NN area)) (PP (IN under) (NP (DT the) (NNP ROC) (NN curve)))) (CC and) (NP (CD 77.0) (NN %) (NN sensitivity))) (PP (IN at) (NP (NP (CD one) (JJ false) (JJ positive)) (PP (IN per) (NP (NN patient))))) (PP (IN in) (NP (NNP FROC) (NN analysis)))) (. .))
